Fujii, Yasutoshi
Ono, Atsushi
Hayes, C. Nelson
Aikata, Hiroshi
Yamauchi, Masami
Uchikawa, Shinsuke
Kodama, Kenichiro
Teraoka, Yuji
Fujino, Hatsue
Nakahara, Takashi
Murakami, Eisuke
Miki, Daiki
Okamoto, Wataru
Kawaoka, Tomokazu
Tsuge, Masataka
Imamura, Michio
Chayama, Kazuaki
Funding for this research was provided by:
Japan Society for the Promotion of Science (KAKENHI (Grant Number 17K15948))
Article History
Received: 19 April 2021
Accepted: 11 June 2021
First Online: 26 June 2021
Declarations
:
: The study protocol was approved by the Hiroshima University ethical committee (approval number were E-726-2 and HI-98) in accordance with the Declaration of Helsinki (27). All patients provided written informed consent.
: Not applicable.
: Potential competing interests: KC received lecture fees from Bristol-Myers Squibb, MSD, AbbVie, Gilead, and Sumitomo Dainippon Pharma and received grants from Bristol-Myers Squibb, Sumitomo Dainippon Pharma, MSD, AbbVie, TORAY, Eisai, Janssen Pharmaceutical, Daiichi-Sankyo, Roche, Otsuka Pharmaceutical, and Mitsubishi-Tanabe Pharma during the conduct of the study.